WO2000078298A2 - Programming ovulation by administering estrogen such as estradiol - Google Patents
Programming ovulation by administering estrogen such as estradiol Download PDFInfo
- Publication number
- WO2000078298A2 WO2000078298A2 PCT/EP2000/005665 EP0005665W WO0078298A2 WO 2000078298 A2 WO2000078298 A2 WO 2000078298A2 EP 0005665 W EP0005665 W EP 0005665W WO 0078298 A2 WO0078298 A2 WO 0078298A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mammal
- estrogen
- human
- exogenous
- dosing regimen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Definitions
- the present invention relates to methods of programming ovulation, measuring or controlling follicular phase length, preventing conception, facilitating fertility, treating infertility, synchronizing early follicular phase assessments, and scheduling late follicular phase clinical evaluations with exogenous estrogen or substance that causes estrogen release.
- Ovulation is the process where an ovum or ova are released from the ovaries.
- the timing of ovulation within the menstrual cycle is critical for fertilization. Since the life span of both spermatozoa and the unfertilized ovum is limited, fertilization must take place within hours after ovulation if conception is to occur during that menstrual cycle .
- the menstrual cycle can be divided into three phases on the basis of endocrine events: the follicular, the ovulatory and the luteal phases.
- the follicular phase extends from the first day of menses to the day before the LH surge, a massive preovulatory release of luteinizing hormone (LH, a gonadotropin) by the pituitary gland.
- LH luteinizing hormone
- FSH follicle stimulating hormone
- estradiol (E 2 ) and estrone (Ei) increases slowly at first, then accelerates to reach a peak on the day before the LH surge.
- the rise in estrogen levels is accompanied by a decrease in FSH levels.
- LH levels rise, culminating in the LH surge.
- a smaller increase in FSH secretion occurs simultaneously, but its significance is not understood.
- estradiol levels decrease while progesterone levels continue to increase.
- the LH surge typically lasting 36 to 48 hours, leads to the final maturation of the ovarian Graafian follicle, follicular rupture and discharge of the ovum or ova from the mature Graafian follicle some 16 to 32 hours after the onset of the LH surge.
- the post- ovulatory ovarian follicle cells are luteinized to form a corpus luteum.
- a marked increase in progesterone secretion by the corpus luteum occurs during the luteal phase, along with a smaller increase in estrogen levels.
- LH and FSH levels decline throughout most of the luteal phase. From the end of the luteal phase through the beginning of the follicular phase in the next menstrual cycle, a period referred to as the intercycle interval or luteal-follicular transition (LFT) , FSH levels rise to initiate follicular growth for the next menstrual cycle.
- LFT luteal-follicular transition
- the present invention provides the ability to program the menstrual cycle or natural ovulation, notably in ART procedures and/or other infertility treatments.
- the present invention relates to a method of programming ovulation in the menstrual cycle of a mammal comprising: administering to the mammal exogenous estrogen, or a substance that causes estrogen release, in a dosing regimen effective to duplicate luteal-phase levels of estrogen.
- the present invention further relates to a method of programming ovulation in the menstrual cycle of a mammal to fall on a preset date comprising:
- the present invention also relates to a method of measuring or controlling follicular phase length in a mammal comprising:
- the present invention relates to a method of preventing conception in a mammal comprising: administering to the mammal an effective dosing regimen of exogenous estrogen or a substance that causes estrogen release .
- the present invention further relates to a method of facilitating fertility in a mammal, comprising: administering to the mammal an effective dosing regimen of exogenous estrogen or a substance that causes estrogen release .
- the present invention also relates to a method of treating infertility in a mammal, comprising: administering to the mammal an effective dosing regimen of exogenous estrogen or a substance that causes estrogen release .
- the present invention relates to a method of synchronizing an early follicular phase assessment to the functional onset of follicular phase in a mammal, comprising: (i) selecting a preset date for performing the early follicular phase assessment; and (ii) administering to the mammal exogenous estrogen, or a substance that causes estrogen release, in a dosing regimen effective to cause intercycle FSH elevation to occur on the preset date.
- the present invention relates to a method of scheduling a late follicular phase clinical evaluation in a mammal, comprising:
- Effective amount refers to the amount required to produce the desired effect.
- Effective dosing regimen refers to the timing, sequence, route and dosage of drug delivery required to produce the desired effect.
- Animal refers to a living organism having sensation and the power of voluntary movement, and which requires for its existence oxygen and organic food. Examples include, without limitation, members of the human, equine, porcine, bovine, murine , canine, or feline species. In the case of a human, an "animal” may also be referred to as a "patient” .
- “Mammal” refers to a warm-blooded vertebrate animal.
- “Facilitating fertility” includes, without limitation, increasing the rate of conception or improving fertility in an animal .
- Treating infertility includes, without limitation, alleviating infertility, increasing the rate of conception or improving fertility in an animal with decreased or impaired fertility or proven infertility.
- Preventing conception includes, without limitation, reducing the rate of conception and/or facilitating or improving the efficacy of contraception in an animal.
- Consymptothermal includes any drug, technique or device for preventing conception or impregnation. Examples include, without limitation, barrier contraceptives, oral contraceptives and natural planning methods (periodic abstinence) such as the calendar rhythm and symptothermal methods .
- exogenous E 2 can regulate intercycle FSH levels.
- De Ziegler, D. et al . "Controlled Preparation of the Endometrium with Exogenous Estradiol and Progesterone in Women Having Functioning Ovaries", Fertil . Ste ⁇ l . (1991) 56:851-5, demonstrated that physiological amounts of exogenous E 2 inhibit follicular recruitment and growth for up to 2 weeks after the onset of the last menstrual period.
- Le Nestour, E. et al . "Role of Estradiol m the Rise m Follicle-Stimulating Hormone Levels during the Luteal-Follicular Transition", J. Clin . Endoc ⁇ nol . Metab .
- the present invention provides methods of using exogenous estrogen or a substance that causes release of estrogen to program ovulation or onset of new menstrual cycles, and to measure the true duration of follicular phase (intercycle FSH elevation - LH surge interval) .
- the present invention relates to a method of programming ovulation in the menstrual cycle of an animal comprising: administering to the animal exogenous estrogen, or a substance that causes estrogen release, in a dosing regimen effective to duplicate luteal-phase levels of estrogen.
- the present invention further relates to a method of programming ovulation in the menstrual cycle of an animal to fall on a preset date comprising:
- inventive methods are believed to program ovulation or the onset of new menstrual cycles by controlling intercycle FSH elevation.
- the inventive methods offer a simple means for timing clinical evaluations and/or treatments such as PCT's,
- the inventive methods can be used to prime endometrial receptivity for frozen embryo transfers by administering exogenous estrogen, or a substance that causes estrogen release, in a dosing regimen effective to prevent follicular recruitment.
- the dosing regimen duplicates luteal-phase levels of estrogen.
- the methods further comprise administering an effective amount of progesterone after administering the estrogen or substance that causes estrogen release.
- inventive methods can be used to synchronize early follicular phase assessments, including baseline ultrasound, FSH, inhibin and E 2 measurements, to the functional onset of the follicular phase (the intercycle FSH elevation) .
- inventive methods can be used to schedule clinical evaluations of the late follicular phase, including PCT's and utero-tubal contractility assessments .
- the present invention also relates to a method of measuring or controlling follicular phase length in an animal comprising:
- the follicular phase length (time interval from intercycle FSH rise to LH surge) is a potentially important parameter of ovarian function.
- the inventive methods can be used to predict reproductive potential and/or diagnose menstrual abnormalities, ovulatory dysfunctions and menopause.
- the inventive methods can be used to induce, stimulate or inhibit ovulation.
- Ovulation induction and/or stimulation can be useful in facilitating fertility and treating infertility, particularly ovulatory dysfunctions including, without limitation, polycystic ovary syndrome, chronic anovulation, hypothalamic amenorrhea and luteal phase deficiency.
- the present invention further relates to a method of facilitating contraception or treating infertility in an animal, comprising: administering to the animal an effective dosing regimen of exogenous estrogen or a substance that causes estrogen release.
- the present invention further relates to a method of preventing conception in an animal comprising: administering to the animal an effective dosing regimen of exogenous estrogen or a substance that causes estrogen release .
- the inventive method may be used in conjunction with other forms of contraception, including natural family planning methods which require abstinence from coitus during fertile periods.
- the instant invention may substantially improve the reliability of predicting the timing of peak fertile periods.
- the animal is preferably a mammal, more preferably a human having a menstrual cycle varying from 25-35 days.
- exogenous estrogens used in the inventive methods include, without limitation, biogenic estrogens (e.g., estradiol, estrone, estriol) , synthetic estrogens (e.g., EE or mestranol) and other estrogens known in the art.
- biogenic estrogens e.g., estradiol, estrone, estriol
- synthetic estrogens e.g., EE or mestranol
- a preferred exogenous estrogen is estradiol valerate (E 2 valerate) .
- the estrogen or substance that causes estrogen release may be administered by any means known to a person of ordinary skill in the art.
- the estrogen or substance that causes estrogen release may be administered by a single dose, multiple discrete doses or continuous infusion.
- the specific dose level for any particular patient will vary depending upon a variety of factors, including the activity and the possible toxicity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration.
- any dosing regimen known to a person of ordinary skill for regulating the timing, sequence, route and dosage of drug delivery can be used and repeated as necessary to effect treatment.
- Such regimen may include pretreatment and/or co-administration with one or more additional therapeutic agent (s) either (i) together in a single formulation, or (ii) separately in individual formulations designed for optimal release rates of their respective active agent.
- PCT pre-program post-coital tests
- PCT pre-program post-coital tests
- E 2 valerate Treatment with exogenous E 2 was initiated on the earlier of (i) day 25 of the previous menstrual cycle or (ii) approximately 3-5 days before the anticipated menses.
- the last day of E 2 treatment was arbitrarily called FDO (functional day 0) and served as reference for numbering days in the follicular phase from FD1 onward. Women were informed that if they were already pregnant, no risk of malformation existed as E 2 valerate is commonly prescribed to pregnant women.
- a baseline vaginal ultrasound was performed on FDO.
- Ovarian volumes were sorted into “largest” and "smallest". It was assumed that the smaller ovarian volume represented the ovary not carrying the previous corpus luteum (Kyei-Mensah, A.
- Vaginal ultrasound was repeated on FD13. Follicles > 10 mm were measured and described. On FD13 , follicles _> 16 were considered "ovulatory" and were counted. In addition, the amount of cervical mucus was assessed and graded from + to +++ : + indicated some sonoluscent mucus identifiable in the cervical canal; +++ was recorded when the entire length of the cervical canal was markedly dilated by sono- transparent mucus; ++ represented intermediary results. Any fluid in the cul-de-sac was identified and reported. Plasma FSH, LH and E 2 were measured on FDO, FD3 and FD9.
- Plasma LH, E 2 and P were measured on FD13.
- FSH and LH increments in response to E 2 withdrawal from FDO to FD3 were calculated and expressed as ⁇ F ⁇ H and ⁇ LH, respectively.
- Plasma FSH and LH were measured using solid-phase immunoassay kits (Chiron Diagnostics Corporation, Norwood, MA, USA) .
- the intraassay and interassay coefficients of variation (CV) were 2.8% and 4.9% for FSH, and 4.7% and 5.0% for LH, respectively.
- Table I also shows treatment information such as the duration between the onset of menses and end of E 2 treatment (FDO) (duration of FSH suppression by E 2 ) .
- FDO E 2 treatment
- Hormone levels and ultrasound findings on FDO, FD3 , FD9 and FD13 appear in Table II. The results were sorted according to whether evidence was obtained of preovulatory LH surge (ovulation) (group A) , previous ovulation (group B) , or no ovulation (group C) on FD13. As shown in Table II, 19 of 26 women (73%) had a preovulatory LH surge on FD13.
- the treatment was designed to program preovulatory testing (e.g., post-coital test) on a Friday.
- the interval from menses to the end of E 2 treatment was not different (certainly not longer) in women who had a short follicular phase (mean, 3.5 days; range, 1-6 days) as compared with the rest of the population (mean ⁇ SEM, 4.9 ⁇ 2.5 days; range, 1-12 days) .
- Baseline ultrasounds on FDO showed no evidence of follicular growth (follicle > 10 mm) in all the participating women.
- the data also confirms that the apparent variability in follicular phase length results mainly from variability in the timing of intercycle FSH elevation.
- the follicular phase length when properly measured by determining the time interval from intercycle FSH rise to LH surge, was as constant as the luteal phase.
- four of the seven women whose plasma LH levels were low on FD13 showed evidence that ovulation had already occurred. These women had truly short follicular phases.
- FD13 none of them showed follicles > 12mm, fluid was identified in the cul-de-sac, plasma P levels were elevated and plasma E 2 had dropped profoundly compared with values on FD9.
- the remaining three women with low LH values and no ovulatory follicle on FD13 also had low P levels, indicating they had not ovulated.
- the amplitude of the FSH signal in response to E 2 withdrawal, or ⁇ FSH was 1.0, 1.1 and 2.1 mlU/mL, respectively. These values were lower than those seen in women who had an ovulatory response on FD13 and in whom ⁇ FSH was 3.1 ⁇ 0.8 mlU/mL (mean ⁇ SEM).
- the smaller increase in FSH triggered by E 2 withdrawal appeared to be insufficient to initiate follicular growth.
- menstrual cycle length was 34, 35 and 35 days, respectively, in these three patients, findings that are at the higher end of the 25- 35 day limit.
- women whose menstrual cycles are naturally long appear more likely to have minimal intercycle FSH signals in response to E 2 withdrawal, a phenomenon possibly instrumental to their tendency for long menstrual cycles.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA02000127A MXPA02000127A (en) | 1999-06-21 | 2000-06-20 | Programming ovulation. |
CA002377609A CA2377609C (en) | 1999-06-21 | 2000-06-20 | Programming ovulation |
AU56839/00A AU5683900A (en) | 1999-06-21 | 2000-06-20 | Programming ovulation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13978399P | 1999-06-21 | 1999-06-21 | |
US60/139,783 | 1999-06-21 | ||
US59360300A | 2000-06-12 | 2000-06-12 | |
US09/593,603 | 2000-06-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000078298A2 true WO2000078298A2 (en) | 2000-12-28 |
WO2000078298A3 WO2000078298A3 (en) | 2001-08-02 |
Family
ID=26837532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/005665 WO2000078298A2 (en) | 1999-06-21 | 2000-06-20 | Programming ovulation by administering estrogen such as estradiol |
Country Status (6)
Country | Link |
---|---|
AU (1) | AU5683900A (en) |
CA (1) | CA2377609C (en) |
CO (1) | CO5180654A1 (en) |
MX (1) | MXPA02000127A (en) |
PE (1) | PE20010640A1 (en) |
WO (1) | WO2000078298A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8425892B2 (en) | 2001-10-29 | 2013-04-23 | Columbia Laboratories, Inc. | Extended, controlled-release pharmaceutical compositions using charged polymers |
EP2117554B1 (en) | 2007-02-06 | 2016-07-13 | Columbia Laboratories (Bermuda) Limited | Progesterone for the prevention of preterm birth |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0737477A1 (en) * | 1993-12-27 | 1996-10-16 | Akzo Nobel N.V. | Percutaneously absorbable preparation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3547774B2 (en) * | 1993-06-28 | 2004-07-28 | 積水化学工業株式会社 | Transdermal formulation |
-
2000
- 2000-06-20 MX MXPA02000127A patent/MXPA02000127A/en unknown
- 2000-06-20 WO PCT/EP2000/005665 patent/WO2000078298A2/en active Application Filing
- 2000-06-20 AU AU56839/00A patent/AU5683900A/en not_active Abandoned
- 2000-06-20 PE PE2000000615A patent/PE20010640A1/en not_active Application Discontinuation
- 2000-06-20 CA CA002377609A patent/CA2377609C/en not_active Expired - Fee Related
- 2000-06-21 CO CO00046437A patent/CO5180654A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0737477A1 (en) * | 1993-12-27 | 1996-10-16 | Akzo Nobel N.V. | Percutaneously absorbable preparation |
Non-Patent Citations (5)
Title |
---|
HANDELSMAN, DAVID J. ET AL: "Oestradiol enhances testosterone-induced suppression of human spermatogenesis" HUM. REPROD. (2000), 15(3), 672-679 , XP000986414 * |
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 04, 31 May 1995 (1995-05-31) & JP 07 010759 A (SEKISUI CHEM CO LTD), 13 January 1995 (1995-01-13) * |
SALEM, MOHAMED LABIB ET AL: "Beta- estradiol -induced decrease in IL-12 and TNF-.alpha. expression suppresses macrophage functions in the course of Listeria monocytogenes infection in mice" INT. J. IMMUNOPHARMACOL. (1999), 21(8), 481-497 , XP000981869 * |
SUTTON, D. J. ET AL: "Prevention of pregnancy in bitches following unwanted mating: a clinical trial using low dose estradiol benzoate" J. REPROD. FERTIL., SUPPL. (1997), 51(REPRODUCTION IN DOGS, CATS AND EXOTIC CARNIVORES), 239-243 , XP000986432 * |
WOOLFSON, A. D. ET AL: "Design of an intravaginal ring for the controlled delivery of 17.beta.- estradiol as its 3-acetate ester" J. CONTROLLED RELEASE (1999), 61(3), 319-328 , XP000982079 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8425892B2 (en) | 2001-10-29 | 2013-04-23 | Columbia Laboratories, Inc. | Extended, controlled-release pharmaceutical compositions using charged polymers |
EP2117554B1 (en) | 2007-02-06 | 2016-07-13 | Columbia Laboratories (Bermuda) Limited | Progesterone for the prevention of preterm birth |
Also Published As
Publication number | Publication date |
---|---|
CA2377609C (en) | 2009-04-21 |
AU5683900A (en) | 2001-01-09 |
CA2377609A1 (en) | 2000-12-28 |
MXPA02000127A (en) | 2003-01-28 |
CO5180654A1 (en) | 2002-07-30 |
WO2000078298A3 (en) | 2001-08-02 |
PE20010640A1 (en) | 2001-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kuang et al. | Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization | |
Neveu et al. | Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization | |
Edelstein et al. | Progesterone levels on the day of human chorionic gonadotropin administration in cycles with gonadotropin-releasing hormone agonist suppression are not predictive of pregnancy outcome | |
Fisher et al. | A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women | |
Schriock et al. | Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin) | |
Daya | Luteal support: progestogens for pregnancy protection | |
Randall et al. | Cervical mucus score and in vitro sperm mucus interaction in spontaneous and clomiphene citrate cycles | |
Ginsburg | Luteal phase defect: Etiology, diagnosis, and management | |
Okewole et al. | Effect of single administration of levonorgestrel on the menstrual cycle | |
Mitwally et al. | Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization–embryo transfer | |
Agarwal et al. | Clomiphene citrate with intrauterine insemination: is it effective therapy in women above the age of 35 years? | |
Matorras et al. | Treatment of the male with follicle-stimulating hormone in intrauterine insemination with husband's spermatozoa: a randomized study. | |
Martinez et al. | Pregnancy rates after timed intercourse or intrauterine insemination after human menopausal gonadotropin stimulation of normal ovulatory cycles: a controlled study | |
Bakas et al. | Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation | |
Damario et al. | Crinone 8% vaginal progesterone gel results in lower embryonic implantation efficiency after in vitro fertilization-embryo transfer | |
JPS6141451A (en) | In vitro fertilizing method | |
Maclin et al. | Progesterone: estradiol ratios at implantation in ongoing pregnancies, abortions, and nonconception cycles resulting from ovulation induction | |
Herman et al. | The benefits of mid-luteal addition of human chorionic gonadotrophin in in-vitro fertilization using a down-regulation protocol and luteal support with progesterone | |
US7402558B2 (en) | Method for aiding implantation or decreasing miscarriage rate | |
CA2377609C (en) | Programming ovulation | |
de Ziegler et al. | Programming ovulation in the menstrual cycle by a simple innovative approach: back to the future of assisted reproduction | |
Stamatelou et al. | Abnormal progesterone and corticotropin releasing hormone levels are associated with preterm labour | |
Lemaire | The luteinized unruptured follicle syndrome: anovulation in disguise | |
Lo Monte et al. | Luteal phase support for assisted reproductive technologies: between past, present and future | |
Tay et al. | The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2377609 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/000127 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |